Related Experiment Video
Updated: Apr 17, 2026
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
White matter hyperintensities, cognitive impairment and dementia: an update
Niels D Prins1, Philip Scheltens1
1Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.
Abstract:
White matter hyperintensities (WMHs) in the brain are the consequence of cerebral small vessel disease, and can easily be detected on MRI. Over the past three decades, research has shown that the presence and extent of white matter hyperintense signals on MRI are important for clinical outcome, in terms of cognitive and functional impairment. Large, longitudinal population-based and hospital-based studies have confirmed a dose-dependent relationship between WMHs and clinical outcome, and have demonstrated a causal link between large confluent WMHs and dementia and disability. Adequate differential diagnostic assessment and management is of the utmost importance in any patient, but most notably those with incipient cognitive impairment. Novel imaging techniques such as diffusion tensor imaging might reveal subtle damage before it is visible on standard MRI. Even in Alzheimer disease, which is thought to be primarily caused by amyloid, vascular pathology, such as small vessel disease, may be of greater importance than amyloid itself in terms of influencing the disease course, especially in older individuals. Modification of risk factors for small vessel disease could be an important therapeutic goal, although evidence for effective interventions is still lacking. Here, we provide a timely Review on WMHs, including their relationship with cognitive decline and dementia.
Insights
White matter hyperintensities (WMHs), visible on MRI, are linked to cognitive decline and dementia. Managing small vessel disease risk factors may be crucial for brain health, though effective interventions are still under investigation.
Area of Science:
- Neurology
- Radiology
- Geriatrics
Background:
- White matter hyperintensities (WMHs) are markers of cerebral small vessel disease, detectable via MRI.
- Research over 30 years confirms WMHs correlate with cognitive and functional impairment.
- Large studies show a dose-dependent relationship between WMHs and clinical outcomes, including dementia and disability.
Purpose of the Study:
- To review the current understanding of white matter hyperintensities (WMHs).
- To explore the relationship between WMHs and cognitive decline, dementia, and disability.
- To discuss the role of small vessel disease in neurological conditions.
Main Methods:
- Review of longitudinal population-based and hospital-based studies.
- Analysis of MRI findings, including standard MRI and diffusion tensor imaging.
- Examination of the association between WMHs and clinical outcomes.
Main Results:
- A causal link exists between confluent WMHs and dementia/disability.
- WMHs show a dose-dependent relationship with cognitive and functional impairment.
- Vascular pathology (small vessel disease) may significantly influence Alzheimer's disease progression.
Conclusions:
- WMHs are critical indicators of cerebral small vessel disease and clinical outcomes.
- Early detection and differential diagnosis of WMHs are important, especially in patients with cognitive impairment.
- Targeting small vessel disease risk factors is a potential therapeutic strategy, requiring further research for effective interventions.
More Related Videos
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
05:12A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
Published on: November 22, 2024
Related Concept Videos
01:30Dementia
The progression of dementia is generally gradual....
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:30Cognitive Development During Adulthood
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:22Alzheimer's Disease: Treatment
01:11Cerebrum: Anatomical Overview II